Oncology Drugs Market: Global Industry Analysis and Forecast 2021-2026

October 27, 2021

A new report has been published by Stratview Research, titled, “Oncology Drugs Market” The experts authoring this report have made an effort at providing in-depth information on leading growth drivers, restrictions, challenges, current and upcoming trends, and opportunities to offer a comprehensive assessment of the global Oncology Drugs Market. Users can use the analysis included in this report to plan effective growth strategies and prepare for future challenges beforehand.

Market segmentation

Market segmentation has been done correctly to help the users define and better understand their target audiences and ideal customers. Market segmentation in this report allows you to identify the right market for your products and then target your marketing more effectively.

Therapy Trends

Based on therapy, the global oncology drugs market has been classified into chemotherapy, targeted therapy, and immunotherapy.

• Among these, the targeted therapy segment witnessed the highest market share in 2020 and is likely to register a healthy CAGR during the review period.
• This is mainly ascribed to the identification of molecular targets of cancer cells.
• Recent developments in cellular technology and gene therapy have further contributed to improving the understanding of tumor cells and their metabolism at the molecular level.

Regional Trends

By region, the North America market garnered the largest market share in 2020 and is projected to grow at a robust CAGR during the review period.

• This can be attributed to rising healthcare expenditure, presence of large patient population, early adoption of advance drugs, and increasing senior population, promulgate the product region in the region.
• Moreover, rise in awareness related to different cancers and a surge in the R&D & innovation activities and further boosts the regional growth.

As the novel coronavirus (COVID-19) crisis takes over the world, our team of market analysts is continuously tracking the changes in the markets, as well as the industry behaviours of the consumers globally and their estimates about the latest market trends and forecasts are being done after considering the impact of this pandemic.

Competitive landscape

Relying on data to make business decisions and to have a competitive advantage, is a critical aspect every key player needs to be familiar with. The report throws light on the competitive scenario of the global Oncology Drugs Market along with a list of Key players.

Here are few –

• F. Hoffmann-La Roche AG (Switzerland),
• Novartis AG (Switzerland),
• Bristol-Myers Squibb Company (The U.S),
• Merck & Co., Inc. (The U.S),
• Johnson & Johnson (The U.S),
• Pfizer Inc. (The U.S),
• AstraZeneca (UK),
• AbbVie Inc. (The U.S),
• Astellas Pharma Inc. (Japan), and
• CELGENE CORPORATION (The U.S).

Report Features -

This market report includes the following features –

• Market structure: Overview, industry life cycle analysis, supply chain analysis.
• Market environment analysis: Growth drivers and constraints.
• Market trend and forecast analysis.
• Competitive landscape and dynamics: Market share, Product portfolio, New Product Launches, M&As etc.
• Attractive market segments and associated growth opportunities.
• Emerging trends.

Custom Research:

Stratview research offers custom research services across the sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to sales@stratviewresearch.com

About Stratview Research –

Stratview Research is a leading market research firm that offers wide range of services like syndicated market reports, consulting, sourcing intelligence, and customer research, etc. Stratview Research’s offerings include comprehensive market intelligence in the form of research reports, and consulting services. Our team which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 500 companies.

Author : Emily